Ratings CStone Pharmaceuticals

Equities

2616

KYG2588M1006

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 EDT			5-day change	1st Jan Change
0.9 ^HKD	0.00%		+5.88%	-60.35%

04-24	Cstone Pharmaceuticals Logs Lower Loss for 2023, Shares Up By Nearly 5%	MT
04-23	CStone Pharmaceuticals Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The stock, which is currently worth 2024 to 0.62 times its sales, is clearly overvalued in comparison with peers.
For several months, analysts have been revising their EPS estimates roughly upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CSTONE PHARMACEUTICALS	-60.35%	146M	-
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B	B+
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B	B+
ARGENX SE	+1.69%	22.15B	B
BIONTECH SE	-17.37%	21.02B	B+
GENMAB A/S	-9.30%	18.15B	A-
WUXI APPTEC CO., LTD.	-41.01%	16.74B	A-
BEIGENE, LTD.	-14.85%	16.05B	B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B	C+
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes